Veracyte Signs a Multi-Year Agreement with AstraZeneca
AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia
Shots:
- Veracyte collaborates with Acerta Pharma, a hematology research and development of AstraZeneca for providing genomic information for supporting development of oncology therapeutics
- On Dec 03, 2019 the company reported acquisition of its diagnostics rights to the NanoString nCounter platform and genomic tests for breast cancer and lymphoma
- The focus of the agreement is to expand the global footprints and the capability to treat cancer
Click here to read full press release/ article | Ref: Veracyte | Image: Signbox